Hermann Nabi, PhD, HDR, is a regular researcher in the Oncology division at CHU de Québec-Université Laval Research Center and Assistant Professor of Epidemiology at the Department of Social and Preventive Medicine at the Faculty of Medicine of Université Laval. Prior to joining the Center and Université Laval in 2016, Dr. Nabi headed the Research Department of Social and Human Sciences, Epidemiology, Public Health at the Institut National du Cancer(INCa) and was a regular researcher at l’Institut National de la Santé et de la Recherche Médicale(INSERM U.1018) in France.

His team’s work focuses on precision medicine, this emerging medical approach for disease prevention and treatment that takes into account individual differences in genes, environment and lifestyle for each person. With advances in genomics and the advent of new molecular biology technologies, precision medicine is attracting a lot of attention and has become an area of ​​strong international competition. However, despite the large volume and unprecedented rate of gene or biomarker discoveries, relatively few have reached the bedside or contributed to improving the health of populations. This relative poor performance could be explained by the fact that only a small proportion (about 3%) of all published global research addresses issues related to the integration of genomics innovations into health and disease prevention. For this reason, the ultimate goal of Dr. Nabi’s team is to generate evidence to facilitate a successful and responsible integration of precision medicine innovations into health care and prevention, particularly for cancer.

To achieve this goal, his work is organized around three main objectives:

1) Characterize the mechanisms and organizational implications of the progressive adoption of innovations in precision medicine in oncology,

2) Evaluate the impact of diagnostic and therapeutic innovations in precision medicine on the quality of life and clinical outcomes of cancer patients and the effectiveness for the health system,

3) Develop and evaluate intervention methods to support the integration of innovations, which takes into account patients and populations’ preferences, economic, accessibility and impact issues, in a knowledge transfer perspective.

The originality of this research program lies in its interdisciplinary approach, which combines a variety of skills and methodological tools to answer questions that are at the interface of several scientific fields. This approach proposes a new way of approaching translational research (the transfer of discoveries from laboratory to bedside), through the use of concepts, models and methods  the human and social sciences, epidemiology, public health, health services research and implementation science.

Hôpital Saint-Sacrement
1050, Chemin Ste-Foy
Québec, Qc
Canada G1S 4L8
104 entries « 11 of 11 »

Nabi H, Consoli SM, Chiron M, Lafont S, Chastang JF, Zins M, Lagarde E

Aggressive/hostile personality traits and injury accidents: an eight-year prospective study of a large cohort of French employees -- the GAZEL cohort

Journal Article

Psychol Med, 36 (3), 2006.

Abstract | Links:

Nabi H, Gueguen A, Chiron M, Lafont S, Zins M, Lagarde E

Awareness of driving while sleepy and road traffic accidents: prospective study in GAZEL cohort

Journal Article

BMJ, 333 (7558), 2006.

Abstract | Links:

Parmentier G, Chastang JF, Nabi H, Chiron M, Lafont S, Lagarde E

Road mobility and the risk of road traffic accident as a driver. The impact of medical conditions and life events

Journal Article

Accid Anal Prev, 37 (6), 2005.

Abstract | Links:

Nabi H, Consoli SM, Chastang JF, Chiron M, Lafont S, Lagarde E

Type A behavior pattern, risky driving behaviors, and serious road traffic accidents: a prospective study of the GAZEL cohort

Journal Article

Am J Epidemiol, 161 (9), 2005.

Abstract | Links:

104 entries « 11 of 11 »
Signaler des ajouts ou des modifications

Active projects

  • Exploring the impact for COVID-19 pandemic on women with breast cancer in Quebec, from 2021-12-01 to 2023-09-30
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II), from 2017-11-01 to 2024-03-31
  • Vers des trajectoires de soins en cancer du sein personnalisées en fonction du risque et des besoins des patientes: une étude de faisabilité et d'acceptabilité, from 2023-04-01 to 2025-03-31
  • What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer, from 2022-01-15 to 2024-01-14

Recently finished projects

  • Enjeux de l’intégration de la Médecine de Précision en Oncologie : mieux comprendre pour mieux agir (teMPO), from 2018-07-01 to 2022-06-30
  • Pilot study of a community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast, from 2019-10-01 to 2023-03-01
  • Quand innovations technologique et organisationnelle vont de pair: Un modèle collaboratif pour rendre l'oncogénétique plus agile, accessible et efficiente, from 2020-04-01 to 2022-03-31
Data provided by the Université Laval research projects registery